Literature DB >> 22959460

Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study.

Casper P Hagen1, Sonja Vestergaard, Anders Juul, Niels Erik Skakkebæk, Anna-Maria Andersson, Katharina M Main, Niels Henrik Hjøllund, Erik Ernst, Jens Peter Bonde, Richard A Anderson, Tina Kold Jensen.   

Abstract

OBJECTIVE: To evaluate whether circulating levels of antimüllerian hormone (AMH) predict fecundability in young healthy women.
DESIGN: Prospective cohort study.
SETTING: General community. PATIENT(S): A total of 186 couples who intended to discontinue contraception to become pregnant were followed until pregnancy or for six menstrual cycles. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Fecundability was evaluated by the monthly probability of conceiving (i.e., fecundability ratio [FR]). In addition, circulating levels of LH, FSH, T, and sex hormone-binding globulin (SHBG) were evaluated in 158 of 186 women. RESULT(S): Fifty-nine percent of couples conceived during the study period. Compared to the reference group of women with medium AMH (AMH quintiles 2-4), fecundability did not differ significantly in women with low AMH (AMH quintile 1) (FR 0.81; 95% confidence interval [CI] 0.44-1.40). In contrast, women with high AMH (AMH quintile 5) had reduced fecundability (FR 0.62; 95% CI 0.39-0.99) after adjustment for covariates (woman's age, body mass index [BMI], smoking, diseases affecting fecundability, and oligozoospermia). Irregular menstrual cycles were more prevalent in women with high AMH compared with women with low or medium AMH levels, and they had higher levels of LH (geometric mean: 8.4 vs. 5.3 IU/L) and LH:FSH ratio (2.4 vs. 1.8). After exclusion of women with irregular cycles, women with high AMH still had reduced fecundability (FR 0.48; 95% CI 0.27-0.85) and elevated LH:FSH ratio (2.4 vs. 1.7). CONCLUSION(S): Low AMH in healthy women in their mid-20s did not predict reduced fecundability. Even after exclusion of women with irregular cycles, the probability of conceiving was reduced in women with high AMH.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959460     DOI: 10.1016/j.fertnstert.2012.08.008

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  38 in total

1.  New perspectives on the role of anti-Müllerian hormone (AMH) in women.

Authors:  Renato Pasquali
Journal:  Ann Transl Med       Date:  2018-12

2.  Chemotherapy-related damage to ovarian reserve in childhood cancer survivors: interpreting the evidence.

Authors:  Edgardo Somigliana; Monica Terenziani; Francesca Filippi; Alice Bergamini; Fabio Martinelli; Giorgia Mangili; Fedro Peccatori; Paolo Vercellini
Journal:  J Assist Reprod Genet       Date:  2018-10-25       Impact factor: 3.412

3.  Mitochondrial DNA copy number in peripheral blood: a potential non-invasive biomarker for female subfertility.

Authors:  Andrea Busnelli; Debora Lattuada; Raffaella Rossetti; Alessio Paffoni; Luca Persani; Luigi Fedele; Edgardo Somigliana
Journal:  J Assist Reprod Genet       Date:  2018-08-17       Impact factor: 3.412

4.  Increased androgen, anti-Müllerian hormone, and sporadic anovulation in healthy, eumenorrheic women: a mild PCOS-like phenotype?

Authors:  Lindsey A Sjaarda; Sunni L Mumford; Kerri Kissell; Karen C Schliep; Ahmad O Hammoud; Neil J Perkins; Jennifer Weck; Jean Wactawski-Wende; Enrique F Schisterman
Journal:  J Clin Endocrinol Metab       Date:  2014-02-28       Impact factor: 5.958

5.  Prediction of ovarian aging using ovarian expression of BMP15, GDF9, and C-KIT.

Authors:  Min Jung Park; Jun-Woo Ahn; Ki Hyung Kim; Junghee Bang; Seung Chul Kim; Jae Yi Jeong; Ye Eun Choi; Chang-Woon Kim; Bo Sun Joo
Journal:  Exp Biol Med (Maywood)       Date:  2020-03-29

6.  Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer.

Authors:  Massimo Giusti; Miranda Mittica; Paola Comite; Claudia Campana; Stefano Gay; Michele Mussap
Journal:  Endocrine       Date:  2018-01-04       Impact factor: 3.633

Review 7.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

8.  Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle.

Authors:  Pin-Yao Lin; Fu-Jen Huang; Fu-Tsai Kung; Hsin-Ju Chiang; Yu-Ju Lin; Yi-Chi Lin; Kuo-Chung Lan
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

9.  Antimüllerian hormone as a risk factor for miscarriage in naturally conceived pregnancies.

Authors:  Brianna M Lyttle Schumacher; Anne Marie Z Jukic; Anne Z Steiner
Journal:  Fertil Steril       Date:  2018-06-02       Impact factor: 7.329

10.  Predicting fertility with antimüllerian hormone: is a cutoff value adequate?

Authors:  Katherine S Anderson; James H Segars
Journal:  Fertil Steril       Date:  2012-10-01       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.